Introduction Welcome to the UCB Newsroom, your source for the latest updates, press releases, and stories that showcase our commitment to advancing science and improving patient lives.Stay informed about our recent breakthroughs, partnerships, and innovations through our features and news updates. Latest press releases The press releases are intended for media and financial analysts Press release 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study... Read More Press release 3 Mar 2026 UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody Read More Press release 26 Feb 2026 Strong Execution Fueling Sustained Company Growth Read More Interested in more? Access our media image selection or contact us for particular requests.The UCB media relations team responds to calls and emails from professional journalists only. View all downloadable resources Contact us
Press release 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study... Read More
Press release 3 Mar 2026 UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody Read More
